COEP Coeptis Therapeutics, Inc.
Healthcare$16.40+0.00%ClosedMarket Cap: $57.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.76
P/S
40.76
EV/EBITDA
-4.83
DCF Value
$3.31
FCF Yield
-13.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.2%
Operating Margin
-912.4%
Net Margin
-839.7%
ROE
-89.6%
ROA
-60.0%
ROIC
-71.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $113.8K | 60.3% | $-3.9M | $-4.0M | $— | — |
| Q4 null | $862.0K | 94.8% | $-2.0M | $-1.6M | $— | — |
| FY null | $1.4M | 86.7% | $-13.0M | $-11.9M | $— | — |
| Q3 null | $237.4K | 81.0% | $-2.5M | $-2.7M | $— | — |
| Q2 null | $200.7K | 77.5% | $-4.5M | $-3.5M | $— | — |
| Q1 null | $62.9K | 28.2% | $-4.1M | $-3.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.2M | $-1.9M | $— | — |
| FY null | $0.00 | NaN% | $-10.1M | $-10.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.1M | $-1.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.8M | $-3.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-2.9M | $-3.0M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-3.4M | $-3.8M | $-0.11 | — |